表紙
市場調査レポート

2型糖尿病治療薬市場:変化する治療アルゴリズムと競争の激化が成長を推し進める

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

発行 GBI Research 商品コード 287727
出版日 ページ情報 英文 123 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
2型糖尿病治療薬市場:変化する治療アルゴリズムと競争の激化が成長を推し進める Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
出版日: 2013年10月18日 ページ情報: 英文 123 Pages
概要

当レポートでは、世界の2型糖尿病治療薬市場について調査分析し、現在/将来の2型糖尿病治療と診断の動向、主な上市製品、開発パイプライン分析、地域別の市場予測、最近の業界取引に関する情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 疫学
  • 症状
  • 病因
  • 病態生理学
  • 併存疾患と合併症
  • 分類
  • 予後
  • 診断
  • 治療効果の評価
  • 治療アルゴリズム

第3章 主な上市製品

  • メトホルミン
  • DPP-4阻害薬
  • GLP-1受容体作動薬
  • スルホニル尿素薬
  • チアゾリジン薬
  • 持続型インスリン
  • SGLT-2阻害薬
  • 上市製品のヒートマップ

第4章 2型糖尿病のパイプライン

  • パイプライン全体
  • 薬効分類
  • 発症率減少
  • 開発プログラムの失敗の理由
  • 臨床試験の期間
  • 臨床試験の規模
  • 有望なパイプライン薬
  • パイプライン製品のヒートマップ
  • 結論

第5章 市場予測

  • 世界市場
    • 治療利用パターン
    • 市場規模
  • 米国
    • 治療利用パターン
    • 年間治療費(ACT)
    • 市場規模
  • 欧州主要5ヶ国
    • 治療利用パターン
    • 年間治療費(ACT)
    • 市場規模
  • 日本
    • 治療利用パターン
    • 年間治療費(ACT)
    • 市場規模
  • 促進要因と障壁
    • 促進要因
    • 障壁

第6章 取引と戦略的統合

  • ライセンス取引
  • 共同開発取引

第7章 付録

図表

目次
Product Code: GBIHC305MR

GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019". There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

  • A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
  • In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
  • Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers and barriers for market growth

Reasons to buy

  • Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
  • Understand the strengths and weaknesses of each product
  • Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Abstract

Type 2 Diabetes Market to Grow Significantly, While Remaining Highly Competitive

The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 10.2%, forecasts business intelligence provider GBI Research.

The company's latest report* states that the US currently has the highest market share, which will rise from $12.7 billion in 2012 to $27.2 billion by 2019, at a CAGR of 11.6%, followed by the top five EU markets (UK, France, Germany, Italy and Spain), which will grow from $4.5 billion to $7.1 billion, at a CAGR of 6.8%.

This increase, according to GBI Research, is due to the anticipated approval of products in relatively novel treatment classes, such as GLP-1 agonists, DPP-4 and SGLT-2 inhibitors. Should these expensive drug classes capture substantial market shares, this would be expected to result in an even more robust level of market growth.

Furthermore, due to the increase in the number of obesity cases and with people living longer, the prevalence of type 2 diabetes is also expected to rise.

Dominic Trewartha, GBI Research's Associate Analyst, says: "The strong forecast for the type 2 diabetes market is reliant upon the ability of late-stage pipeline drugs, such as gemigliptin, to reach expectations created by promising clinical trial results, and of newly marketed products including Nesina and Tradjenta to capture a significant share of the market. In order to do this, they will need to balance clinical efficacy with safety and tolerability profiles."

However, the sulfonylureas and metformin classes, both widely used among type 2 diabetes patients, are strongly penetrated by generic and low-cost products, presenting a potential major barrier to the market.

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

This report provides an in-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. It includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Epidemiology
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Pathophysiology
  • 2.5. Co-morbidities and Complications
  • 2.6. Classification
  • 2.7. Prognosis
  • 2.8. Diagnosis
  • 2.9. Assessing Treatment Effectiveness
  • 2.10. Treatment Algorithm
    • 2.10.1. The Role of Insulin in Type 2 Diabetes
    • 2.10.2. Non-insulin Diabetic Drugs
    • 2.10.3. Other Drugs

3. Key Marketed Products

  • 3.1. Metformin
  • 3.2. DPP-4 Inhibitors
    • 3.2.1. Januvia (sitagliptin) - Merck & Co
    • 3.2.2. Tradjenta (linagliptin) - Boehringer Ingelheim
    • 3.2.3. Onglyza (saxagliptin) - Bristol-Myers Squibb and AstraZeneca
    • 3.2.4. Nesina (alogliptin) - Takeda
    • 3.2.5. Galvus (vildagliptin) - Novartis
    • 3.2.6. Tenelia (teneligliptin) - Daiichi Sankyo and Mitsubishi Tanabe
  • 3.3. GLP-1 Agonists
    • 3.3.1. Byetta and Bydureon (exenatide) - Bristol-Myers Squibb
    • 3.3.2. Lyxumia (lixisenatide) - Sanofi
    • 3.3.3. Victoza (liraglutide) - Novo Nordisk
  • 3.4. Sulfonylureas
    • 3.4.1. Glimepiride
    • 3.4.2. Gliclazide
  • 3.5. Thiazolidinediones
    • 3.5.1. Actos (pioglitazone) - Takeda Pharmaceuticals Limited
    • 3.5.2. Avandia (rosiglitazone) - GlaxoSmithKline
  • 3.6. Long-Acting Insulins
    • 3.6.1. Lantus (insulin glargine) - Sanofi
    • 3.6.2. Levemir (insulin detemir) - Novo Nordisk
    • 3.6.3. Tresiba and Ryzodeg (Insulin degludec) - Novo Nordisk
  • 3.7. SGLT-2 Inhibitors
    • 3.7.1. Forxiga (dapagliflozin) - Bristol-Myers Squibb
    • 3.7.2. Invokana (canagliflozin) - Janssen
  • 3.8. Heat Map for Marketed Products

4. Pipeline for Type 2 Diabetes

  • 4.1. Overall Pipeline
  • 4.2. Therapeutic Classes
  • 4.3. Rate of Attrition
    • 4.3.1. Failure Rate by Molecule Type
    • 4.3.2. Failure Rate by Therapeutic Class
  • 4.4. Reasons for Failure of Developmental Programs
  • 4.5. Clinical Trial Duration
    • 4.5.1. Duration by Molecule Type
    • 4.5.2. Duration by Therapeutic Class
  • 4.6. Clinical Trial Size
    • 4.6.1. Clinical Trial Size by Molecule Type
    • 4.6.2. Clinical Trial Size by Therapeutic Class
  • 4.7. Promising Drugs in the Pipeline
    • 4.7.1. LY-2189265 (dulaglutide) - Eli Lilly
    • 4.7.2. Albiglutide - GlaxoSmithKline
    • 4.7.3. LC15-044 (gemigliptin) - LG Life Sciences
    • 4.7.4. TAK-875 - Takeda
    • 4.7.5. Ipragliflozin - Astellas Pharma
    • 4.7.6. LX-4211 - Lexicon Pharmaceuticals
    • 4.7.7. Imeglimin - Poxel SA
    • 4.7.8. CCX-140-B - ChemoCentryx
    • 4.7.9. Semaglutide - Novo Nordisk A/S
    • 4.7.10. PC-DAC Exendin-4 - ConjuChem Biotechnologies
  • 4.8. Heat Map for Pipeline Products
  • 4.9. Conclusion

5. Market Forecast to 2019

  • 5.1. Global Market
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Market Size
  • 5.2. US
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Top Five Countries of Europe
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Japan
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Drivers and Barriers
    • 5.5.1. Drivers
    • 5.5.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. TransTech Pharma Enters into Licensing Agreement with Forest Laboratories
    • 6.1.2. Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052
    • 6.1.3. Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim
    • 6.1.4. Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475
    • 6.1.5. Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company
    • 6.1.6. Metabolex Enters into Licensing Agreement with Sanofi
    • 6.1.7. Wellstat Enters into a License Agreement with Sanofi
    • 6.1.8. CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi
    • 6.1.9. Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals
    • 6.1.10. Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747
    • 6.1.11. Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077
    • 6.1.12. Glenmark Pharma Enters into Licensing Agreement with Merck KGaA
    • 6.1.13. Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals
    • 6.1.14. Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici
    • 6.1.15. Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin
    • 6.1.16. Nastech Pharma Enters into Licensing Agreement with Amylin Pharma
    • 6.1.17. Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk
    • 6.1.18. Array BioPharma Enters into a Licensing Agreement with Amgen
    • 6.1.19. Theratechnologies Enters into a Licensing Agreement with OctoPlus
    • 6.1.20. Diabetica Enters into a Licensing Agreement with Amylin
    • 6.1.21. Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health
    • 6.1.22. Aradigm Enters into a Licensing Agreement with Novo Nordisk
    • 6.1.23. Santarus Enters into a License Agreement with Shore Therapeutics
    • 6.1.24. Depomed Enters into a Licensing Agreement with Boehringer Ingelheim
    • 6.1.25. Depomed Enters into a Licensing Agreement with Merck
    • 6.1.26. Depomed Enters into a Licensing Agreement with Teva
  • 6.2. Co-development Deals
    • 6.2.1. Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim
    • 6.2.2. AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb
    • 6.2.3. Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals
    • 6.2.4. Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide
    • 6.2.5. Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals
    • 6.2.6. Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim
    • 6.2.7. Intercept Pharma Enters into Co-development Agreement with Servier
    • 6.2.8. Transition Therapeutics Enters into an Agreement with Eli Lilly
    • 6.2.9. Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb
    • 6.2.10. Biocompatibles Enters into a Co-Development Agreement with AstraZeneca

7. Appendix

  • 7.1. All Pipeline Drugs by Stage of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical and IND-filed
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III and Pre-registration
    • 7.1.6. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. UK
    • 7.2.4. France
    • 7.2.5. Germany
    • 7.2.6. Italy
    • 7.2.7. Spain
    • 7.2.8. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References for Heat Maps
  • 7.6. References
  • 7.7. Research Methodology
    • 7.7.1. Coverage
    • 7.7.2. Secondary Research
    • 7.7.3. Primary Research
  • 7.8. Therapeutic Landscape
  • 7.9. Epidemiology-based Forecasting
  • 7.10. Market Size by Geography
  • 7.11. Geographical Landscape
  • 7.12. Pipeline Analysis
  • 7.13. Expert Panel Validation
  • 7.14. Contact Us
  • 7.15. Disclaimer

List of Tables

  • Table 1: The Relationship between HbA1c and Mean Blood Glucose
  • Table 2: Pipeline Drugs (Discovery)
  • Table 3: Pipeline Drugs (Preclinical and IND-filed)
  • Table 4: Pipeline Drugs (Phase I)
  • Table 5: Pipeline Drugs (Phase II)
  • Table 6: Pipeline Drugs (Phase III)
  • Table 7: Pipeline Drugs (Undisclosed stage of development)
  • Table 8: Type 2 Diabetes Therapeutics Market, Global, Market Forecast, 2012-2019
  • Table 9: Type 2 Diabetes Therapeutics Market, US, Market Forecast, 2012-2019
  • Table 10: Type 2 Diabetes Therapeutics Market, UK, Market Forecast, 2012-2019
  • Table 11: Type 2 Diabetes Therapeutics Market, France, Market Forecast, 2012-2019
  • Table 12: Type 2 Diabetes Therapeutics Market, Germany, Market Forecast, 2012-2019
  • Table 13: Type 2 Diabetes Therapeutics Market, Italy, Market Forecast, 2012-2019
  • Table 14: Type 2 Diabetes Therapeutics Market, Spain, Market Forecast, 2012-2019
  • Table 15: Type 2 Diabetes Therapeutics Market, Japan, Market Forecast, 2012-2019
  • Table 16: Type 2 Diabetes Therapeutics Market, Global, References for Heat Maps, 2013

List of Figures

  • Figure 1: Type 2 Diabetes Therapeutics Market, Global, Composite Treatment Algorithm, 2013
  • Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales of Januvia and Janumet ($m), 2006-2012
  • Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales of Onglyza ($m), 2009-2012
  • Figure 4: Type 2 Diabetes Therapeutics Market, Global, Sales of Galvus ($m), 2007-2012
  • Figure 5: Type 2 Diabetes Therapeutics Market, Global, Sales of Byetta ($m), 2005-2010
  • Figure 6: Type 2 Diabetes Therapeutics Market, Global, Sales of Victoza ($m), 2009-2012
  • Figure 7: Type 2 Diabetes Therapeutics Market, Global, Sales of Actos ($m), 2003-2011
  • Figure 8: Type 2 Diabetes Therapeutics Market, Global, Sales of Avandia ($m), 1999-2012
  • Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales of Lantus ($m), 2003-2012
  • Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales of Levemir (As reported by Novo Nordisk), 2008-2012
  • Figure 11: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013
  • Figure 12: Type 2 Diabetes Therapeutics Market, Global, Sales of Novel Products ($m, Years after Approval), 1998-2012
  • Figure 13: Type 2 Diabetes Therapeutics Pipeline Overview
  • Figure 14: Type 2 Diabetes Therapeutics Market, Global, Therapeutic Classes
  • Figure 15: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2006-2013
  • Figure 16: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Molecule Type, 2006-2013
  • Figure 17: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Therapeutic Class, 2006-2013
  • Figure 18: Type 2 Diabetes Therapeutics Market, Global, Reasons for Clinical Trial Failure (%), 2006-2013
  • Figure 19: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Duration, 2006-2013
  • Figure 20: Type 2 Diabetes Therapeutics Market, Mean Clinical Trial Duration by Therapeutic Class, Global, 2006-2013
  • Figure 21: Type 2 Diabetes Therapeutics Market, Mean and Median Clinical Trial Size, Global, 2006-2013
  • Figure 22: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Molecule Type, Global, 2006-2013
  • Figure 23: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Therapeutic Class, Global, 2006-2013
  • Figure 24: Type 2 Diabetes Therapeutics Market, Heat Map of Pipeline Products
  • Figure 25: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013
  • Figure 26: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2012-2019
  • Figure 27: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012-2019
  • Figure 28: Type 2 Diabetes Therapeutics Market, US, Treatment Usage Patterns, 2012-2019
  • Figure 29: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012-2019
  • Figure 30: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2012-2019
  • Figure 31: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2012-2019
  • Figure 32: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Market Size ($m), 2012-2019
  • Figure 33: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2012-2019
  • Figure 34: Type 2 Diabetes Therapeutics Market, Japan, Market Size ($m), 2012-2019
  • Figure 35: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006-2013
  • Figure 36: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 37: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 38: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006-2013
  • Figure 39: Type 2 Diabetes Therapeutics Market, Global, Co-development Deals, 2006-2012
  • Figure 40: GBI Research Market Forecasting Model
Back to Top